The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Blocking Soluble Tumor Necrosis Factor Signaling with Dominant-Negative Tumor Necrosis Factor Inhibitor Attenuates Loss of Dopaminergic Neurons in Models of Parkinson's Disease
Open accessAbstract
The mechanisms that trigger or contribute to loss of dopaminergic (DA) neurons in Parkinson's disease (PD) remain unclear and controversial. Elevated levels of tumor necrosis factor (TNF) in CSF and postmortem brains of PD patients and animal models of PD implicate this proinflammatory cytokine in the pathophysiology of the disease; but a role for TNF in mediating loss of DA neurons in PD has not been clearly demonstrated. Here, we report that neutralization of soluble TNF (solTNF)in vivo with the engineered dominant-negative TNF compound XENP345 (a PEGylated version of the TNF variant A145R/I97T) reduced by 50% the retrograde nigral degeneration induced by a striatal injection of the oxidative neurotoxin 6-hydroxydopamine (6-OHDA). XENP345 was neuroprotective only when infused into the nigra, not the striatum. XENP345/6-OHDA rats displayed attenuated amphetamine-induced rotational behavior, indicating preservation of striatal dopamine levels. Similar protective effects were observed with chronic in vivo coinfusion of XENP345 with bacterial lipopolysaccharide (LPS) into the substantia nigra, confirming a role for solTNF-dependent neuroinflammation in nigral degeneration. In embryonic rat midbrain neuron/glia cell cultures exposed to LPS, even delayed administration of XENP345 prevented selective degeneration of DA neurons despite sustained microglia activation and secretion of solTNF. XENP345 also attenuated 6-OHDA-induced DA neuron toxicity in vitro. Collectively, our data demonstrate a role for TNF in vitro and in vivo in two models of PD, and raise the possibility that delaying the progressive degeneration of the nigrostriatal pathway in humans is therapeutically feasible with agents capable of blocking solTNF in early stages of PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glutamate neurotoxicity and diseases of the nervous system
CHOI, D. (1988) · Neuron · doi:10.1016/0896-6273(88)90162-6 · Cited by 7,972
Triple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126
West, M. J., Slomianka, L., & Gundersen, H. J. G. (1991) · The Anatomical Record · doi:10.1002/ar.1092310411 · Cited by 2,994
McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
MOLECULAR PATHOPHYSIOLOGY OF PARKINSON'S DISEASE
Moore, D. J., West, A. B., Dawson, V. L., & Dawson, T. M. (2005) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.28.061604.135718 · Cited by 1,280
Pasparakis, M., Alexopoulou, L., Episkopou, V, & Kollias, G. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.4.1397 · Cited by 1,160
Cytokines and acute neurodegeneration
Allan, S. M., & Rothwell, N. J. (2001) · Nature Reviews Neuroscience · doi:10.1038/35094583 · Cited by 1,123
TNFα promotes proliferation of oligodendrocyte progenitors and remyelination
Arnett, H. A., Mason, J., Marino, M., Suzuki, K., Matsushima, G. K., & Ting, J. P.-Y. (2001) · Nature Neuroscience · doi:10.1038/nn738 · Cited by 1,012
García-Ruiz, C., Colell, A., Marí, M., Morales, A., & Fernández-Checa, J. C. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.17.11369 · Cited by 806
Kim, R. H., Smith, P. D., Aleyasin, H., Hayley, S., Mount, M. P., Pownall, S., Wakeham, A., You-Ten, A. J., Kalia, S. K., Horne, P., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501282102 · Cited by 701
Cited by
Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease
Turner, M. D., Nedjai, B., Hurst, T., & Pennington, D. J. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2014.05.014 · Cited by 2,162
Neuroinflammation in Parkinson’s disease: A target for neuroprotection?
Hirsch, E. C., & Hunot, S. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70062-6 · Cited by 1,984
Inflammation and immune dysfunction in Parkinson disease
Tansey, M. G., Wallings, R. L., Houser, M. C., Herrick, M. K., Keating, C. E., & Joers, V. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-022-00684-6 · Cited by 1,382
Self-citationTNF biology, pathogenic mechanisms and emerging therapeutic strategies
Kalliolias, G. D., & Ivashkiv, L. B. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.169 · Cited by 1,387
Tansey, M. G., & Goldberg, M. S. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.11.004 · Cited by 1,045
Self-citationInflammation in Alzheimer Disease--A Brief Review of the Basic Science and Clinical Literature
Wyss-Coray, T., & Rogers, J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006346 · Cited by 975
Neuroinflammation in Parkinson's disease and its potential as therapeutic target
Wang, Q., Liu, Y., & Zhou, J. (2015) · Translational Neurodegeneration · doi:10.1186/s40035-015-0042-0 · Cited by 884
Microglia-mediated neuroinflammation in neurodegenerative diseases
Subhramanyam, C. S., Wang, C., Hu, Q., & Dheen, S. T. (2019) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2019.05.004 · Cited by 870
McCoy, M. K., & Tansey, M. G. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-45 · Cited by 847
Self-citationDoes neuroinflammation fan the flame in neurodegenerative diseases?
Frank-Cannon, T. C., Alto, L. T., McAlpine, F. E., & Tansey, M. G. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-47 · Cited by 751
Self-citationInterrelation of Oxidative Stress and Inflammation in Neurodegenerative Disease: Role of TNF
Fischer, R., & Maier, O. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/610813 · Cited by 731
Glial reactions in Parkinson's disease
McGeer, P. L., & McGeer, E. G. (2008) · Movement Disorders · doi:10.1002/mds.21751 · Cited by 701
Immune activation in brain aging and neurodegeneration: too much or too little?
Lucin, K. M., & Wyss-Coray, T. (2009) · Neuron · doi:10.1016/j.neuron.2009.08.039 · Cited by 679
Heterogeneity of CNS myeloid cells and their roles in neurodegeneration
Prinz, M., Priller, J., Sisodia, S. S., & Ransohoff, R. M. (2011) · Nature Neuroscience · doi:10.1038/nn.2923 · Cited by 674
Tansey, M. G., McCoy, M. K., & Frank-Cannon, T. C. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.07.004 · Cited by 583
Self-citationMicroglial cell dysregulation in brain aging and neurodegeneration
von Bernhardi, R., Eugenín-von Bernhardi, L., & Eugenín, J. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00124 · Cited by 556
Qin, X.-Y., Zhang, S.-P., Cao, C., Loh, Y. P., & Cheng, Y. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.2742 · Cited by 554
TNF and its receptors in the CNS: The essential, the desirable and the deleterious effects
Probert, L. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.06.038 · Cited by 495
Blood-Brain Barrier and Delivery of Protein and Gene Therapeutics to Brain
Pardridge, W. M. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00373 · Cited by 405
Montgomery, S. L., & Bowers, W. J. (2012) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-011-9287-2 · Cited by 366
Neurodegeneration and Inflammation—An Interesting Interplay in Parkinson’s Disease
Marogianni, C., Sokratous, M., Dardiotis, E., Hadjigeorgiou, G. M., Bogdanos, D., & Xiromerisiou, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228421 · Cited by 366
Apoptotic cell death in disease—Current understanding of the NCCD 2023
Vitale, I., Pietrocola, F., Guilbaud, E., Aaronson, S. A., Abrams, J. M., Adam, D., Agostini, M., Agostinis, P., Alnemri, E. S., Altucci, L., et al. (2023) · Cell Death & Differentiation · doi:10.1038/s41418-023-01153-w · Cited by 361
Koprich, J. B., Reske-Nielsen, C., Mithal, P., & Isacson, O. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-8 · Cited by 355
González, H., Elgueta, D., Montoya, A., & Pacheco, R. (2014) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2014.07.012 · Cited by 352
The Role of Innate and Adaptive Immunity in Parkinson's Disease
Kannarkat, G. T., Boss, J. M., & Tansey, M. G. (2013) · Journal of Parkinson’s Disease · doi:10.3233/jpd-130250 · Cited by 324
“Administration of soluble DN-TNF via osmotic pump or lentiviral overexpression in the SN shows protection in 6-OHDA models [182, 183].”
Self-citationContributions of central and systemic inflammation to the pathophysiology of Parkinson's disease
Collins, L. M., Toulouse, A., Connor, T. J., & Nolan, Y. M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.01.028 · Cited by 306
Neuroinflammation and oxidative stress: Co-conspirators in the pathology of Parkinson’s disease
Taylor, J. M., Main, B. S., & Crack, P. J. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2012.12.016 · Cited by 303
The influence of microglia on the pathogenesis of Parkinson's disease
Long-Smith, C. M., Sullivan, A. M., & Nolan, Y. M. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2009.08.001 · Cited by 296
Microglial phenotypes in Parkinson’s disease and animal models of the disease
Joers, V., Tansey, M. G., Mulas, G., & Carta, A. R. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.04.006 · Cited by 285
Self-citationTumor necrosis factor-alpha mediated signaling in neuronal homeostasis and dysfunction
Park, K. M., & Bowers, W. J. (2010) · Cellular Signalling · doi:10.1016/j.cellsig.2010.01.010 · Cited by 283
Cellular Senescence in Neurodegenerative Diseases
Martínez-Cué, C., & Rueda, N. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00016 · Cited by 281
McAlpine, F. E., Lee, J.-K., Harms, A. S., Ruhn, K. A., Blurton-Jones, M., Hong, J., Das, P., Golde, T. E., LaFerla, F. M., Oddo, S., et al. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.01.006 · Cited by 268
Self-citationRole of Microglia in Neurological Disorders and Their Potentials as a Therapeutic Target
Du, L., Zhang, Y., Chen, Y., Zhu, J., Yang, Y., & Zhang, H.-L. (2017) · Molecular Neurobiology · doi:10.1007/s12035-016-0245-0 · Cited by 262
Parkin Deficiency Increases Vulnerability to Inflammation-Related Nigral Degeneration
Frank-Cannon, T. C., Tran, T., Ruhn, K. A., Martinez, T. N., Hong, J., Marvin, M., Hartley, M., Treviño, I., O'Brien, D. E., Casey, B., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3001-08.2008 · Cited by 261
Self-citationTNF-α signaling in glaucomatous neurodegeneration
Tezel, G. (2008) · Progress in Brain Research · doi:10.1016/s0079-6123(08)01128-x · Cited by 261
Microglia in the developing brain: a potential target with lifetime effects
Harry, G. J., & Kraft, A. D. (2012) · NeuroToxicology · doi:10.1016/j.neuro.2012.01.012 · Cited by 250
Norepinephrine: The redheaded stepchild of Parkinson's disease
Rommelfanger, K. S., & Weinshenker, D. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.01.036 · Cited by 255
Role of α-Synuclein in Inducing Innate and Adaptive Immunity in Parkinson Disease
Allen Reish, H. E., & Standaert, D. G. (2015) · Journal of Parkinson’s Disease · doi:10.3233/jpd-140491 · Cited by 244
The role of the LRRK2 gene in Parkinsonism
Li, J.-Q., Tan, L., & Yu, J.-T. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-47 · Cited by 249
“Blocking the early phase of neuroinflammation by minocycline or the application of non-steroidal antiinflammatory drugs, cyclooxygenase-2 (COX-2), soluble tumor necrosis factor or IL-1beta inhibitors attenuates the PD-like disease process which gave strong supporting to this hypothesis [60-63].”
ResultThe lipopolysaccharide Parkinson’s disease animal model: mechanistic studies and drug discovery
Dutta, G., Zhang, P., & Liu, B. (2008) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.2008.00616.x · Cited by 235
Neuroinflammation in Parkinson's disease: role in neurodegeneration and tissue repair
Vivekanantham, S., Shah, S., Dewji, R., Dewji, A., Khatri, C., & Ologunde, R. (2015) · International Journal of Neuroscience · doi:10.3109/00207454.2014.982795 · Cited by 171
Advances in small molecules promoting neurotrophic function
PRICE, R., MILNE, S., SHARKEY, J., & MATSUOKA, N. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.03.005 · Cited by 148
Wang, J., Song, N., Jiang, H., Wang, J., & Xie, J. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.01.021 · Cited by 150
Members, E. W. E., Terron, A., Bal-Price, A., Paini, A., Monnet-Tschudi, F., Bennekou, S. H., Leist, M., & Schildknecht, S. (2018) · Archives of Toxicology · doi:10.1007/s00204-017-2133-4 · Cited by 124
“Blocking TNF-α by expression of TNF-α inhibitor protein protects from DA neuron loss in animal models of PD (McCoy et al. 2006).”
BackgroundClark, I. A., & Vissel, B. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0708-2 · Cited by 123
Tentillier, N., Etzerodt, A., Olesen, M. N., Rizalar, F. S., Jacobsen, J., Bender, D., Moestrup, S. K., & Romero-Ramos, M. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.1636-16.2016 · Cited by 109
Barnum, C. J., Pace, T. W., Hu, F., Neigh, G. N., & Tansey, M. G. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-9 · Cited by 107
“Two structures were examined: the midbrain, a region we have shown to be susceptible to inflammation [39-41], and the hippocampus, a critical player in the stress response [42].”
BackgroundSelf-citationWang, B., Cai, Z., Tao, K., Zeng, W., Lu, F., Yang, R., Feng, D., Gao, G., & Yang, Q. (2016) · Autophagy · doi:10.1080/15548627.2016.1179401 · Cited by 107
Microglia and inflammation: conspiracy, controversy or control?
Fernandes, A., Miller-Fleming, L., & Pais, T. F. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1670-8 · Cited by 103
Hernández-Romero, M. C., Delgado-Cortés, M. J., Sarmiento, M., de Pablos, R. M., Espinosa-Oliva, A. M., Argüelles, S., Bández, M. J., Villarán, R. F., Mauriño, R., Santiago, M., et al. (2012) · NeuroToxicology · doi:10.1016/j.neuro.2012.01.018 · Cited by 100
The Therapeutic Role of Minocycline in Parkinson’s Disease
Cankaya, S., Cankaya, B., Kilic, U., Kilic, E., & Yulug, B. (2019) · Drugs in Context · doi:10.7573/dic.212553 · Cited by 93
The Role of Anti-Inflammatory Agents in Parkinson???s Disease
McGeer, E. G., & McGeer, P. L. (2007) · CNS Drugs · doi:10.2165/00023210-200721100-00001 · Cited by 95
Main, B. S., Zhang, M., Brody, K. M., Ayton, S., Frugier, T., Steer, D., Finkelstein, D., Crack, P. J., & Taylor, J. M. (2016) · Glia · doi:10.1002/glia.23028 · Cited by 92
Non-cell-autonomous Neurotoxicity of α-synuclein Through Microglial Toll-like Receptor 2
Kim, C., Lee, H.-J., Masliah, E., & Lee, S.-J. (2016) · Experimental Neurobiology · doi:10.5607/en.2016.25.3.113 · Cited by 92
“Furthermore, studies have shown that microglia-derived inflammatory molecules, such as TNFα, IL-1β, IL-6, and NO contributed to the acceleration of dopamine neuron degeneration [22-24].”
BackgroundAmin, R., Quispe, C., Docea, A. O., Ydyrys, A., Kulbayeva, M., Durna Daştan, S., Calina, D., & Sharifi-Rad, J. (2022) · Neurochemistry International · doi:10.1016/j.neuint.2022.105376 · Cited by 74
Regulation of the neurodegenerative process associated to Parkinson's disease by CD4+ T-cells
González, H., Contreras, F., & Pacheco, R. (2015) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-015-9618-9 · Cited by 70
Cebrián, C., Loike, J. D., & Sulzer, D. (2014) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2014_356 · Cited by 65
Walia, V., Chaudhary, S. K., & Kumar Sethiya, N. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2020.104939 · Cited by 51
Genetic Defects and Pro-inflammatory Cytokines in Parkinson's Disease
Magnusen, A. F., Hatton, S. L., Rani, R., & Pandey, M. K. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.636139 · Cited by 47
Safety of Plasma Infusions in Parkinson's Disease
Parker, J. E., Martinez, A., Deutsch, G. K., Prabhakar, V., Lising, M., Kapphahn, K. I., Anidi, C. M., Neuville, R., Coburn, M., Shah, N., et al. (2020) · Movement Disorders · doi:10.1002/mds.28198 · Cited by 23
Metadata
- Authors
- McCoy, M. K., Martinez, T. N., Ruhn, K. A., Szymkowski, D. E., Smith, C. G., Botterman, B. R., Tansey, K. E., & Tansey, M. G.
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2006-09-13
- Volume
- 26
- Issue
- 37
- Pages
- 9365-9375
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- OpenAlex
- W2047402066
- Cited by
- 354
- References
- 57
- FWCI
- 11.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.